Reduced Plasma Level of CXC Chemokine Ligand 7 in Patients with Pancreatic Cancer

Matsubara, Junichi; Honda, Kazufumi; Ono, M.; Tanaka, Yoshinori; Kobayashi, Minatsu; Jung, Giman; Yanagisawa, Koji; Sakuma, Tomohiro; Nakamori, Shoji; Sata, Naohiro; Nagai, Hideo; Ioka, Tatsuya; Okusaka, Takuji; Kosuge, Tomoo; Tsuchida, Akihiko; Shimahara, Masashi; Yasunami, Yohichi; Chiba, Tsutomu; Hirohashi, Setsuo; Yamada, Tesshi

doi:10.1158/1055-9965.epi-10-0397

Cited by 44 publications

(41 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). The high efficacy of combining HFMT and 2DICAL for plasma biomarker discovery was shown for the first time in our previous study of pancreatic cancer (17), and the present results further strengthened the credible evidence for the applicability of this combination of methods to all types of future plasma biomarker research. Any biomarker candidate identified by proteomic approaches must be validated using a different method in a statistically sufficient number of cases and controls before it can be considered for clinical application.…”

Section: Discussionsupporting

confidence: 78%

“…This technology is especially advantageous in clinical studies in which a large number of patient samples must be compared. We were able to identify a number of plasma/serum biomarkers with high potential for clinical application using 2DICAL (14)(15)(16)(17)(18). However, the direct analysis of plasma/serum proteins using 2DICAL remains technically challenging.…”

Section: Introductionmentioning

confidence: 99%

“…In this study, we applied a high-performance hollowfiber membrane (HFM) technology to the enrichment of low-molecular weight (LMW) proteins (17,22) and searched for new plasma biomarkers that might be applicable to the early diagnosis of colorectal cancer. The LMW plasma protein fraction is made up of various functional proteins, such as cytokines, chemokines, and peptides and is considered to be a rich unexplored archive of biological information (20).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray

Matsubara

Honda

Ono

et al. 2011

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Background: The aim of this study was to identify a new plasma biomarker for use in early detection of colorectal cancer.Methods: Using the combination of hollow fiber membrane (HFM)-based low-molecular weight protein enrichment and two-dimensional image converted analysis of liquid chromatography and mass spectrometry (2DICAL), we compared the plasma proteome of 22 colorectal cancer patients with those of 21 healthy controls. An identified biomarker candidate was then validated in two larger cohorts [validation-1 (n ¼ 210) and validation-2 (n ¼ 113)] using a high-density reverse-phase protein microarray.Results: From a total of 53,009 mass peaks, we identified 103 with an area under curve (AUC) value of 0.80 or higher that could distinguish cancer patients from healthy controls. A peak that increased in colorectal cancer patients, with an AUC of 0.81 and P value of 0.0004 (Mann-Whitney U test), was identified as a product of the PLIN2 gene [also known as perilipin-2, adipose differentiation-related protein (ADRP), or adipophilin]. An increase in plasma adipophilin was consistently observed in colorectal cancer patients, including those with stage I or stage II disease (P < 0.0001, Welch's t test). Immunohistochemical analysis revealed that adipophilin is expressed primarily in the basal sides of colorectal cancer cells forming polarized tubular structures, and that it is absent from adjacent normal intestinal mucosae.Conclusions: Adipophilin is a plasma biomarker potentially useful for the detection of early-stage colorectal cancer.Impact: The combination of HFM and 2DICAL enables the comprehensive analysis of plasma proteins and is ideal for use in all biomarker discovery studies. Cancer Epidemiol Biomarkers Prev; 20(10); 2195-203. Ó2011 AACR.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray

Matsubara

Honda

Ono

et al. 2011

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…From the evidence available, several chemokine-receptor pairs may be good candidates. A combination of several markers, together with these chemokines, may be promising diagnostic tools, such as CXCL17-ICAM2 [167] and a classical molecular marker for pancreatic cancer, carbohydrate antigen 19-9, together with CXCL7 [168] .…”

Section: Pancreasmentioning

confidence: 99%

“…Perineural invasion and dissemination of neoplastic cells along intra-and extra-pancreatic nerves [163,164] CXCL17 (+ ICAM2) Diagnostic molecular marker [167] CXCL7 (+ CA19-9) Diagnostic molecular marker [168] Colon CXCL4L1 Upregulation in colorectal cancer [115] CCL2 upregulation in mucosa of IBD [169] …”

Section: Cx3cl1cx3cr1mentioning

confidence: 99%

Chemokines, chemokine receptors and the gastrointestinal system

Miyazaki¹,

Takabe²,

Yeudall³

2013

WJG

View full text Add to dashboard Cite

Core tip: The chemokine network makes an attractive target for therapeutic intervention in many tumor types, including those of the gastrointestinal tract. However, we need to define more selective and specific targets, to minimize systemic side effects during treatment. INTRODUCTION Cancer development and progression in the gastrointestinal tractCancer is a disease in which normal cells acquire genetic and epigenetic abnormalities [1,2] , leading to disorientation of conventional processes for the maintenance of normal cell physiology. These aberrant genetic and epigenetic modifications to the normal cell induce abnormal cell motility, proliferation, and survival, eventually enabling these cells to invade into adjacent tissues and even to migrate to regional or distant organs where they may grow continuously as metastatic lesions [3] . For many cancer patients, metastasis is generally the major cause of disease-related death [4,5] . Therefore, it is indispensable to elucidate the basic molecular mechanisms of tumor development to identify effective therapeutic targets, which can possibly reduce the side-effects of treatment, and define useful molecular markers for early detection and prediction of disease course. Especially, the newly emerged concept of personalized medicine may require in-depth assessment of potential therapeutic molecular target(s) in each individual case through analysis of sig- REVIEW Chemokines, chemokine receptors and the gastrointestinal system AbstractThe biological properties of tumor cells are known to be regulated by a multitude of cytokines and growth factors, which include epidermal growth factor receptor agonists and members of the transforming growth factor β family. Furthermore, the recent explosion of research in the field of chemokine function as mediators of tumor progression has led to the possibility that these small, immunomodulatory proteins also play key roles in carcinogenesis and may, therefore, be potential targets for novel therapeutic approaches. In this review, we will summarize recently reported findings in chemokine biology with a focus on the gastrointestinal tract.

show abstract

CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer

Liu

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

It is desirable to have a biomarker which can facilitate low‐dose CT in diagnosis of early stage lung cancer. CTAPIII/CXCL7 is reported to be a potential biomarker for diagnosis of early lung cancer. In this study, we investigated the serum level of CTAPIII/CXCL7 in patients at different stage of lung cancer and the diagnostic efficacy of CTAPIII/CXCL7 in NSCLC. The plasma level of CTAPIII/CXCL7 was assayed by ELISA. CEA, SCCAg, and Cyfra211 were measured using a commercial chemiluminescent microparticle immunoassay. A total of 419 subjects were recruited, including 265 NSCLC patients and 154 healthy individuals. The subjects were randomly assigned to a training set and a test set. Receiver operating characteristic (ROC) and binary logistic regression analyses were conducted to evaluate the diagnostic efficacy and establish diagnostic mathematical model. Plasma CTAPIII/CXCL7 levels were significantly higher in NSCLC patients than in controls, which was independent of the stage of NSCLC. The diagnostic efficiency of CTAPIII/CXCL7 in NSCLC (training set: area under ROC curve (AUC) 0.806, 95% CI: 0.748–0.863; test set: AUC 0.773, 95% CI: 0.711–0.835) was greater than that of SCCAg, Cyfra21‐1, or CEA. The model combining CTAPIII/CXCL7 with CEA, SCCAg, and Cyfra21‐1 was more effective for NSCLC diagnosis than CTAPIII/CXCL7 alone. In addition, plasma level of CTAPIII/CXCL7 may contribute to the early diagnosis of NSCLC. CTAPIII/CXCL7 can be used as a plasma biomarker for the diagnosis of NSCLCs, particularly early stage lung cancer, with relatively high sensitivity and specificity.

show abstract

Reduced Plasma Level of CXC Chemokine Ligand 7 in Patients with Pancreatic Cancer

Cited by 44 publications

References 44 publications

Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray

Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray

Chemokines, chemokine receptors and the gastrointestinal system

CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer

Contact Info

Product

Resources

About